NGL Fine Chem

Who are in the management team of NGL Fine Chem?

As of March 2023, the management team of NGL Fine Chem includes Rahul J Nachane (Managing Director), Rajesh N Lawande (Whole Time Director & CFO), Milind V Shinde (Chairman & Independent Director), Ajita Nachane (Non-Executive Director), Jayaram Sitaram (Non-Executive Independent Director), Pallavi Pednekar (Company Secretary), and Sarala Menon (Independent Director). They oversee the company's operations and strategic direction.

As of March 2023, the management team of NGL Fine Chem includes the following individuals:<BR><BR>1. Rahul J Nachane - Managing Director<BR>2. Rajesh N Lawande - Whole Time Director & CFO<BR>3. Milind V Shinde - Chairman & Independent Director<BR>4. Ajita Nachane - Non-Executive & Non-Independent Director<BR>5. Jayaram Sitaram - Non-Executive & Independent Director<BR>6. Pallavi Pednekar - Company Secretary & Compliance Officer<BR>7. Sarala Menon - Independent Director<BR><BR>This team is responsible for overseeing the operations and strategic direction of the company.

Has NGL Fine Chem declared dividend?

NGL Fine Chem Ltd has declared a 35% dividend, amounting to ₹1.75 per share, with an ex-date of August 16, 2024. While recent total returns have been negative, the company has shown significant positive returns over the past five years.

NGL Fine Chem Ltd has declared a 35% dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 35%<BR>- Amount per share: 1.75<BR>- Ex-date: 16 Aug 24<BR><BR>Dividend Yield: 0.17%.<BR><BR>Total Returns by Period:<BR>In the 6 months period, the price return was -42.05%, with a dividend return of 0%, resulting in a total return of -42.05%.<BR><BR>Over the 1 year period, the price return was -53.0%, accompanied by a dividend return of 0.07%, leading to a total return of -52.93%.<BR><BR>For the 2 years period, the price return was -27.5%, with a dividend return of 0.21%, culminating in a total return of -27.29%.<BR><BR>In the 3 years period, the price return was -41.37%, and the dividend return was 0.21%, resulting in a total return of -41.16%.<BR><BR>During the 4 years period, the price return was -44.93%, with a dividend return of 0.34%, leading to a total return of -44.59%.<BR><BR>In the 5 years period, the price return was 163.89%, accompanied by a dividend return of 2.62%, resulting in a total return of 166.51%.<BR><BR>Overall, while NGL Fine Chem has declared a dividend, the total returns over the shorter periods have been negative, indicating a challenging performance. However, the longer-term returns over five years show a significant positive return, suggesting potential recovery or growth in the future.

Who are the peers of the NGL Fine Chem?

NGL Fine Chem's peers include Sun Pharma, Divi's Lab, Cipla, Torrent Pharma, Dr Reddy's Labs, Venus Remedies, Shukra Pharma, Nectar Lifesci, Medicamen Biotec, and Sakar Healthcare. NGL Fine Chem has average management risk, below-average growth, and the lowest 1-year return at -52.32% among its peers.

Peers: The peers of NGL Fine Chem are Sun Pharma.Inds., Divi's Lab., Cipla, Torrent Pharma, Dr Reddy's Labs, Venus Remedies, Shukra Pharma., Nectar Lifesci., Medicamen Biotec, and Sakar Healthcare.<BR><BR>Quality Snapshot: Excellent management risk is observed at Sun Pharma.Inds., Cipla, and Dr Reddy's Labs, while Average management risk is found at NGL Fine Chem, Venus Remedies, Shukra Pharma., Medicamen Biotec, and Sakar Healthcare. Growth is Excellent for Sun Pharma.Inds., Cipla, and Dr Reddy's Labs, while Below Average growth is seen at NGL Fine Chem, Divi's Lab., Torrent Pharma, Nectar Lifesci., and Medicamen Biotec. Capital Structure is Excellent for Sun Pharma.Inds., Divi's Lab., Cipla, Dr Reddy's Labs, NGL Fine Chem, Venus Remedies, and Medicamen Biotec, while Good capital structure is noted for Torrent Pharma and Shukra Pharma., and Average for Sakar Healthcare.<BR><BR>Return Snapshot: Divi's Lab. has the highest 1-year return at 51.96%, while NGL Fine Chem has the lowest at -52.32%. NGL Fine Chem's return is significantly lower than all its peers. Additionally, Nectar Lifesci., Medicamen Biotec, and NGL Fine Chem have negative six-month returns.

What does NGL Fine Chem do?

NGL Fine Chem Ltd is a Micro Cap manufacturer of pharmaceuticals and intermediates for veterinary and human health, with net sales of 950 Cr and a net profit of 5 Cr as of March 2025. The company was incorporated in 1981 and is based in Mumbai, India.

Overview:<BR>NGL Fine Chem Ltd is a manufacturer of pharmaceuticals and intermediates for usage in veterinary and human health, operating within the Pharmaceuticals & Biotechnology industry and classified as a Micro Cap company.<BR><BR>History:<BR>NGL Fine Chem Ltd was incorporated on December 18, 1981, initially as a Private Limited Company in Maharashtra and later became a Public Limited Company. The latest quarterly results reported net sales and profit for the period ending March 2025.<BR><BR>Financial Snapshot:<BR>Net Sales: 950 Cr (Quarterly Results - Mar 2025) <BR>Net Profit: 5 Cr (Quarterly Results - Mar 2025) <BR>Market Cap: INR 891 Cr (Micro Cap)<BR><BR>Key Metrics:<BR>P/E: 43.00 <BR>Industry P/E: 37 <BR>Dividend Yield: 0.13% <BR>Debt-Equity: 0.03 <BR>Return on Equity: 7.38% <BR>Price to Book: 3.00 <BR><BR>Contact Details:<BR>Address: 301 E Square Subhash Road, Vile Parle (East) Mumbai Maharashtra : 400057 <BR>Tel: +91-22-2663 6450 <BR>Email: cs@nglfinechem.com / info@nglfinechem.com <BR>Website: http://www.nglfinechem.com

Who are the top shareholders of the NGL Fine Chem?

The top shareholder of NGL Fine Chem is Rajesh Lawande, holding 21.89%, with no pledged promoter holdings. Public shareholders include Yashkumar Poonamchand Golechha at 1.05%, while individual investors collectively hold 22.75%; mutual funds and foreign institutional investors have negligible holdings.

The top shareholders of NGL Fine Chem primarily include the promoters, with Rajesh Lawande holding the largest share at 21.89%. There are no pledged promoter holdings. In terms of public shareholders, Yashkumar Poonamchand Golechha is the highest individual shareholder at 1.05%. Additionally, individual investors collectively hold 22.75% of the company's shares. Mutual funds and foreign institutional investors have minimal holdings, with mutual funds holding 0.0% and only one foreign institutional investor also holding 0.0%.

How big is NGL Fine Chem?

As of 24th July, NGL Fine Chem Ltd has a market capitalization of 791.00 Cr, with net sales of 368.30 Cr and a net profit of 20.85 Cr for the latest four quarters. Shareholder's funds are 262.63 Cr and total assets amount to 355.54 Cr as of March 2024.

As of 24th July, NGL Fine Chem Ltd has a market capitalization of 791.00 Cr, categorizing it as a Micro Cap company.<BR><BR>For the latest four quarters, NGL Fine Chem reported Net Sales of 368.30 Cr and a Net Profit of 20.85 Cr.<BR><BR>The latest annual period for the balance sheet is March 2024, with Shareholder's Funds amounting to 262.63 Cr and Total Assets of 355.54 Cr.

Are NGL Fine Chem latest results good or bad?

NGL Fine Chem's latest results show a mixed performance: while it achieved its highest annual operating cash flow in three years and net sales for the quarter, its profit after tax has declined sharply by 54.60% year-on-year, leading to a 'Sell' rating due to concerns over profitability and reliance on non-operating income.

NGL Fine Chem's latest results present a mixed picture. On one hand, the company achieved its highest annual operating cash flow in three years, amounting to Rs 35.82 crore, and reported net sales of Rs 104.19 crore for the quarter, which is the highest in the last five quarters. This indicates a positive trend in sales and operational cash generation.<BR><BR>However, there are significant challenges as well. The profit after tax (PAT) for the last six months has declined sharply by 54.60% year-on-year, which raises concerns about profitability. Additionally, a substantial portion of the profit before tax—over 53%—came from non-operating income, suggesting a reliance on income sources that may not be sustainable.<BR><BR>Overall, while there are some positive signs in terms of sales and cash flow, the decline in profitability and reliance on non-operating income indicate that the financial performance is not strong. The stock is currently rated as a 'Sell', reflecting the market's cautious outlook on the company's future prospects.

Is NGL Fine Chem overvalued or undervalued?

As of August 4, 2025, NGL Fine Chem is considered overvalued with a PE ratio of 38.04, an EV to EBITDA ratio of 23.60, and a Price to Book Value of 2.81, significantly higher than its peers, while also showing a year-to-date return of -28.62%, lagging behind the Sensex's 3.69%.

As of 4 August 2025, the valuation grade for NGL Fine Chem has moved from fair to expensive, indicating a shift towards overvaluation. The company is currently assessed as overvalued, with a PE ratio of 38.04, an EV to EBITDA ratio of 23.60, and a Price to Book Value of 2.81. These figures suggest that the stock is trading at a premium compared to its earnings and book value.<BR><BR>In comparison to its peers, NGL Fine Chem's PE ratio is higher than Sun Pharma's 34.25 and significantly above Cipla's attractive PE of 22.7. The PEG ratio for NGL Fine Chem is notably low at 0.00, indicating a lack of growth expectations, which further supports the overvaluation claim. Additionally, while the stock has shown strong returns over the long term, its recent performance has lagged behind the Sensex, with a year-to-date return of -28.62% compared to the Sensex's 3.69%.

When is the next results date for NGL Fine Chem?

The next results date for NGL Fine Chem is 12 November 2025.

The next results date for NGL Fine Chem is scheduled for 12 November 2025.

How has been the historical performance of NGL Fine Chem?

NGL Fine Chem has shown an upward trend in net sales and total assets from Mar'20 to Mar'25, increasing from 151.69 Cr to 368.26 Cr, but profitability has declined, with profit after tax dropping from 56.72 Cr in Mar'21 to 21.12 Cr in Mar'25. Overall, while sales and assets have grown, the company faces challenges in maintaining profitability.

Answer:<BR>The historical performance of NGL Fine Chem shows a fluctuating trend in key financial metrics over the years.<BR><BR>Breakdown:<BR>NGL Fine Chem's net sales have shown a general upward trend, increasing from 151.69 Cr in Mar'20 to 368.26 Cr in Mar'25, despite a dip in Mar'22. Total operating income followed a similar pattern, reaching 368.26 Cr in Mar'25. The raw material cost has also risen significantly, from 69.75 Cr in Mar'20 to 182.41 Cr in Mar'25, contributing to total expenditure growth from 132.30 Cr in Mar'20 to 334.39 Cr in Mar'25. Operating profit (PBDIT) peaked at 87.76 Cr in Mar'21 but has since declined to 42.50 Cr in Mar'25. Profit before tax mirrored this trend, decreasing from 77.59 Cr in Mar'21 to 27.71 Cr in Mar'25. Profit after tax also saw fluctuations, with a high of 56.72 Cr in Mar'21 and a drop to 21.12 Cr in Mar'25. The company's total liabilities increased from 153.62 Cr in Mar'20 to 433.39 Cr in Mar'25, while total assets rose from 153.62 Cr to 433.39 Cr in the same period. Cash flow from operating activities improved to 35.00 Cr in Mar'25, while net cash inflow/outflow remained stable at 0.00 Cr. Overall, NGL Fine Chem has experienced growth in sales and assets, but profitability has faced challenges in recent years.

Is NGL Fine Chem technically bullish or bearish?

As of December 3, 2025, the trend has shifted to mildly bearish due to bearish signals from MACD, KST, Bollinger Bands, and Dow Theory, despite daily moving averages remaining mildly bullish.

As of 3 December 2025, the technical trend has changed from mildly bullish to mildly bearish. The current stance is mildly bearish, driven by weekly MACD and KST indicators both showing mild bearishness, alongside bearish signals from Bollinger Bands and Dow Theory on a weekly basis. The daily moving averages remain mildly bullish, but the overall trend indicates weakness. The stock has underperformed significantly over the past month and year compared to the Sensex, reinforcing the bearish outlook.

Should I buy, sell or hold NGL Fine Chem Ltd?

Why is NGL Fine Chem Ltd falling/rising?

As of 27-Jan, NGL Fine Chem Ltd's stock price is rising to 1,536.45, up 1.75%. The stock has outperformed the Sensex recently, showing strong momentum despite a decline in investor participation.

As of 27-Jan, NGL Fine Chem Ltd's stock price is rising, currently at 1,536.45, reflecting an increase of 26.45 or 1.75%. This upward movement is supported by several factors. Over the past week, the stock has outperformed the benchmark Sensex, gaining 0.68% while the Sensex declined by 0.39%. Additionally, in the last month, NGL Fine Chem has shown a significant increase of 18.97%, contrasting sharply with the Sensex's drop of 3.74%. Year-to-date, the stock has also risen by 9.05%, while the Sensex has fallen by 3.95%.<BR><BR>Today's performance indicates that NGL Fine Chem has outperformed its sector by 2.08%. The stock is trading above its moving averages across various time frames, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages, which typically signals positive momentum. However, it is important to note that there has been a decline in investor participation, with delivery volume dropping by 57.08% compared to the 5-day average. Despite this, the stock remains liquid enough for trading, indicating that it can still attract investors.<BR><BR>Overall, the combination of strong recent performance relative to benchmarks and moving averages contributes to the stock's rising price.

Which are the latest news on NGL Fine Chem?